Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.63 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.61 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711598 | 1.00 | GNPAT (0.63) | GNPATERAP2LNPEPOPRK1MMP2 | |
| SCHEMBL1711769 | 1.00 | GNPAT (0.63) | GNPATERAP2LNPEPOPRK1MMP2 | |
| SCHEMBL29540649 | 1.00 | GNPAT (0.63) | GNPATERAP2LNPEPOPRK1MMP2 | |
| SCHEMBL1711765 | 1.00 | GNPAT (0.63) | GNPATERAP2LNPEPOPRK1MMP2 | |
| SCHEMBL30051985 | 0.99 | GNPAT (0.62) | GNPATERAP2LNPEPOPRK1MMP2 | |
| SCHEMBL30915103 | 0.99 | GNPAT (0.62) | GNPATERAP2LNPEPOPRK1MMP2 | |
| SCHEMBL29630365 | 0.96 | ERAP2 (0.62) | GNPATERAP2LNPEPOPRK1MMP2 | |
| SCHEMBL7120877 | 0.96 | ERAP2 (0.62) | GNPATERAP2LNPEPOPRK1MMP2 | |
| SCHEMBL29372662 | 0.96 | ERAP2 (0.65) | GNPATERAP2LNPEPOPRK1MMP2 | |
| SCHEMBL29382413 | 0.96 | ERAP2 (0.65) | GNPATERAP2LNPEPOPRK1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560599-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | Syntarga B.V. (NL) | 2005-08-10 | — | — | EP | claimed |
| WO-2004043493-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | SYNTARGA B.V. (NL) | 2004-05-27 | — | — | WO | claimed |
| EP-1370298-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | Syntarga B.V. (NL) | 2003-12-17 | — | — | EP | claimed |
| WO-2002083180-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA B.V. (NL) | 2002-10-24 | — | — | WO | claimed |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| EP-3108886-B1 | CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | SYNTARGA BV (NL) | 2020-06-17 | — | — | EP | disclosed |
| EP-1909846-B1 | TRIAZOLE-CONTAINING RELEASABLE LINKERS, CONJUGATES COMPRISING THE SAME AND PROCESSES FOR THEIR PREPARATION | SYNTARGA BV (NL) | 2018-12-26 | — | — | EP | disclosed |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-17 | — | — | US | disclosed |
| US-9901567-B2 | Substituted CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2018-02-27 | — | — | US | disclosed |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-11-23 | — | — | US | disclosed |
| US-9815784-B2 | CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2017-11-14 | — | — | US | disclosed |
| EP-1909846-A2 | TRIAZOLE-CONTAINING RELEASABLE LINKERS, CONJUGATES THEREOF, AND METHODS OF PREPARATION | Syntarga B.V. (NL) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007089149-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007018431-A2 | TRIAZOLE-CONTAINING RELEASABLE LINKERS AND CONJUGATES COMPRISING THE SAME | SYNTARGA B.V. (NL) | 2007-02-15 | — | — | WO | disclosed |
| EP-1560599-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | Syntarga B.V. (NL) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004043493-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | SYNTARGA B.V. (NL) | 2004-05-27 | — | — | WO | disclosed |
| EP-0961619-A4 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL MYERS SQUIBB CO (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-0961619-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998013059-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | GNPAT 1859/4885ERAP2 2938/4885LNPEP 989/4885 |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | GNPAT 1859/4885ERAP2 2938/4885LNPEP 989/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | GNPAT 1698/4885ERAP2 2981/4885LNPEP 916/4885 |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | GNPAT 1859/4885ERAP2 2938/4885LNPEP 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.